2Xideas AG Sells 21,436 Shares of Bio-Techne Corp

Institutional investor decreases stake in biotechnology company

Mar. 14, 2026 at 7:04am

Got story updates? Submit your updates here. ›

2Xideas AG, an institutional investor, decreased its holdings in Bio-Techne Corp (NASDAQ:TECH) by 31.0% in the third quarter, according to a recent SEC filing. The firm now owns 47,822 shares of the biotechnology company's stock, down from 69,258 shares previously.

Why it matters

This filing provides insight into the investment decisions of 2Xideas AG, a notable institutional investor in the biotechnology sector. Changes in major shareholders' positions can signal shifts in market sentiment or strategic priorities for the company.

The details

According to the 13F filing, 2Xideas AG sold 21,436 shares of Bio-Techne during the third quarter. The firm's remaining stake in the company is valued at $2,660,000 as of the most recent reporting period. Bio-Techne is a global life sciences company that develops and sells reagents, instruments, and services for research, diagnostic, and bioprocessing applications.

  • 2Xideas AG decreased its Bio-Techne holdings in the third quarter of 2026.

The players

2Xideas AG

An institutional investor and hedge fund that has decreased its stake in Bio-Techne Corp.

Bio-Techne Corp

A global life sciences company that develops and sells reagents, instruments, and services for research, diagnostic, and bioprocessing applications.

Got photos? Submit your photos here. ›

The takeaway

This filing highlights the shifting investment landscape in the biotechnology sector, as major institutional investors like 2Xideas AG adjust their portfolios. The changes in ownership could signal broader market trends or strategic considerations for Bio-Techne as it continues to grow its life sciences business.